Literature DB >> 3937575

Salmon-calcitonin nasal spray in Paget's disease of bone: preliminary results in five patients.

J Y Reginster, A Albert, P Franchimont.   

Abstract

The effectiveness of Synthetic Salmon Calcitonin (SSCT) administered as a nasal spray was assessed via clinical, biological, and radiological variables in 5 Pagetic patients during a 6 months course therapy, the results show that intranasal administration does not decrease the activity of SSCT in Paget's disease of bone.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3937575     DOI： 10.1007/bf02554908

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN： 0171-967X            Impact factor:   4.333


  1 in total

1.  A new "kinetic" method for enzyme analysis suitable for automation.

Authors:  K A Trayser; D Seligson
Journal:  Clin Chem       Date:  1969-06       Impact factor: 8.327
  1 in total
  10 in total

1.  Increase of pain threshold by calcitonin during electrical stimulation of the dental pulp. Investigations in healthy volunteers with regard to plasma concentration.

Authors:  K Welzel; D Welzel
Journal:  Schmerz       Date:  1989-09       Impact factor: 1.107

2.  The effect of different doses of nasal salmon calcitonin on plasma cyclic AMP and serum ionized calcium.

Authors:  G Thamsborg; T L Storm; E Brinch; R Sykulski; N Fogh-Andersen; S N Holmegaard; O H Sørensen
Journal:  Calcif Tissue Int       Date:  1990-01       Impact factor: 4.333

3.  Effect of different doses of nasal salmon calcitonin on bone mass.

Authors:  G Thamsborg; T L Storm; R Sykulski; E Brinch; H K Nielsen; O H Sørensen
Journal:  Calcif Tissue Int       Date:  1991-05       Impact factor: 4.333

4.  Intranasal absorption of salmon calcitonin.

Authors:  H Kurose; Y Seino; M Shima; H Tanaka; M Ishida; K Yamaoka; H Yabuuchi
Journal:  Calcif Tissue Int       Date:  1987-11       Impact factor: 4.333

5.  The effect of rectal and nasal administration of salmon calcitonin in normal subjects.

Authors:  T Buclin; J P Randin; A F Jacquet; M Azria; M Attinger; F Gomez; P Burckhardt
Journal:  Calcif Tissue Int       Date:  1987-11       Impact factor: 4.333

6.  Comparison of the acute effect of the intranasal and intramuscular administration of salmon calcitonin in Paget's disease.

Authors:  D González; E Vega; G Ghiringhelli; C Mautalen
Journal:  Calcif Tissue Int       Date:  1987-12       Impact factor: 4.333

Review 7.  Future horizons for calcitonin: a U.S. perspective.

Authors:  J H Carstens; J D Feinblatt
Journal:  Calcif Tissue Int       Date:  1991       Impact factor: 4.333

Review 8.  Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging.

Authors:  S P Clissold; A Fitton; P Chrisp
Journal:  Drugs Aging       Date:  1991 Sep-Oct       Impact factor: 3.923

9.  The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer.

Authors:  W A Lee; R D Ennis; J P Longenecker; P Bengtsson
Journal:  Pharm Res       Date:  1994-05       Impact factor: 4.200

Review 10.  Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.

Authors:  C Gennari; R Nuti; D Agnusdei; A Camporeale; G Martini
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.